Zevra Therapeutics shared its Q3 2026 results, showing a 45% jump in revenue thanks to U.S. sales of myplifa.

Nov 3, 2026, 6:01 PM ETResultsRead the original at Benzinga

Good for ZVRA

Zevra reported 45% Q3 revenue growth, including $34 million in U.S. myplifa sales. Only 300–350 of an estimated 900 U.S. patients are diagnosed, and the infant-use application is planned for 2027; current sales growth and cash support a favorable outlook.

ZVRA · Zevra Therapeutics

AI read · Good for ZVRA

The AI's read

More sales suggest myplifa is reaching more patients, and 197 enrollment forms have come in since launch. Zevra also has more than $270 million in cash and investments to support its plans. Still, only 300 to 350 of an estimated 900 U.S. patients are diagnosed. The infant-use application is planned for Q1 2027, so that expansion is not approved yet.

Get alerts for ZVRA

Follow Zevra Therapeutics (ZVRA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ZVRA

Free on the App Store and Google Play, or on the web.